

## Buparvaquone Formulation

Version 5.1      Revision Date: 2023/09/30      SDS Number: 2091179-00013      Date of last issue: 2023/04/04  
Date of first issue: 2017/10/17

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Buparvaquone Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000

Emergency telephone number : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS Classification

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure : Category 3

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

#### GHS label elements

Hazard pictograms :



Signal word : Danger

## Buparvaquone Formulation

Version 5.1      Revision Date: 2023/09/30      SDS Number: 2091179-00013      Date of last issue: 2023/04/04  
 Date of first issue: 2017/10/17

**Hazard statements** : H315 Causes skin irritation.  
 H319 Causes serious eye irritation.  
 H335 May cause respiratory irritation.  
 H360D May damage the unborn child.  
 H410 Very toxic to aquatic life with long lasting effects.

**Precautionary statements** : **Prevention:**  
 P201 Obtain special instructions before use.  
 P202 Do not handle until all safety precautions have been read and understood.  
 P261 Avoid breathing mist or vapours.  
 P264 Wash skin thoroughly after handling.  
 P271 Use only outdoors or in a well-ventilated area.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
 P302 + P352 IF ON SKIN: Wash with plenty of water.  
 P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
 P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
 P337 + P313 If eye irritation persists: Get medical advice/ attention.  
 P362 + P364 Take off contaminated clothing and wash it before reuse.  
 P391 Collect spillage.

**Storage:**  
 P405 Store locked up.

**Disposal:**  
 P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

| Chemical name          | CAS-No.  | Concentration (% w/w) |
|------------------------|----------|-----------------------|
| N-Methyl-2-pyrrolidone | 872-50-4 | >= 30 -< 60           |

## Buparvaquone Formulation

|                |                              |                              |   |
|----------------|------------------------------|------------------------------|---|
| Version<br>5.1 | Revision Date:<br>2023/09/30 | SDS Number:<br>2091179-00013 | Date of last issue: 2023/04/04<br>Date of first issue: 2017/10/17 |
|----------------|------------------------------|------------------------------|---|

|              |            |              |
|--------------|------------|--------------|
| Buparvaquone | 88426-33-9 | >= 2.5 -< 10 |
|--------------|------------|--------------|

**4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes skin irritation.  
Causes serious eye irritation.  
May cause respiratory irritation.  
May damage the unborn child.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**5. FIREFIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing. Avoid breathing mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.

---

## Buparvaquone Formulation

Version 5.1      Revision Date: 2023/09/30      SDS Number: 2091179-00013      Date of last issue: 2023/04/04  
 Date of first issue: 2017/10/17

Store locked up.  
 Keep tightly closed.  
 Keep in a cool, well-ventilated place.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

| Components   | CAS-No.    | Value type<br>(Form of exposure) | Control parameters / Permissible concentration | Basis    |
|--------------|------------|----------------------------------|--|----------|
| Buparvaquone | 88426-33-9 | TWA                              | 40 µg/m <sup>3</sup> (OEB 3)                   | Internal |
|              |            | Wipe limit                       | 400 µg/100 cm <sup>2</sup>                     | Internal |

## Biological occupational exposure limits

| Components             | CAS-No.  | Control parameters               | Biological specimen | Sampling time  | Permissible concentration | Basis     |
|------------------------|----------|----------------------------------|---------------------|--|---------------------------|-----------|
| N-Methyl-2-pyrrolidone | 872-50-4 | 5-Hydroxy-N-methyl-2-pyrrolidone | Urine               | End of shift (As soon as possible after exposure ceases) | 100 mg/l                  | ACGIH BEI |

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

## Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type  
 Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

**Buparvaquone Formulation**

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- 

**9. PHYSICAL AND CHEMICAL PROPERTIES**

- Appearance : liquid
- Colour : clear, red
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : No data available
- Evaporation rate : No data available
- Flammability (solid, gas) : Not applicable
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

|  |   |  |
|--|---|--|
| Vapour pressure                        | : | No data available  |
| Relative vapour density                | : | No data available  |
| Relative density                       | : | 1 (20 °C)  |
| Density                                | : | No data available  |
| Solubility(ies)                        |   |  |
| Water solubility                       | : | No data available  |
| Partition coefficient: n-octanol/water | : | Not applicable   |
| Auto-ignition temperature              | : | No data available  |
| Decomposition temperature              | : | No data available  |
| Viscosity                              |   |  |
| Viscosity, kinematic                   | : | No data available  |
| Explosive properties                   | : | Not explosive  |
| Oxidizing properties                   | : | The substance or mixture is not classified as oxidizing. |
| Particle size                          | : | Not applicable   |

---

**10. STABILITY AND REACTIVITY**

|                                    |   |  |
|------------------------------------|---|--|
| Reactivity                         | : | Not classified as a reactivity hazard.         |
| Chemical stability                 | : | Stable under normal conditions.                |
| Possibility of hazardous reactions | : | Can react with strong oxidizing agents.        |
| Conditions to avoid                | : | None known.                                    |
| Incompatible materials             | : | Oxidizing agents                               |
| Hazardous decomposition products   | : | No hazardous decomposition products are known. |

---

**11. TOXICOLOGICAL INFORMATION**

|  |   |  |
|--|---|--|
| Information on likely routes of exposure | : | Inhalation<br>Skin contact<br>Ingestion<br>Eye contact |
|--|---|--|

**Acute toxicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

**Buparvaquone Formulation**

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

**Buparvaquone:**

Acute oral toxicity : LD50 (Rat): > 8,000 mg/kg  
LD50 (Mouse): > 50 mg/kg  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50: 2.5 mg/kg  
Application Route: Intravenous

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Result : Skin irritation

**Buparvaquone:**

Species : Mouse  
Result : Mild skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days

**Buparvaquone:**

Result : Mild eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.



**Buparvaquone Formulation**

Version 5.1      Revision Date: 2023/09/30      SDS Number: 2091179-00013      Date of last issue: 2023/04/04  
Date of first issue: 2017/10/17

---

**Components:****N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : negative  
Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 474  
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Hamster  
Application Route: Ingestion  
Method: OECD Test Guideline 475  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

|                   |                       |
|-------------------|-----------------------|
| Species           | : Rat                 |
| Application Route | : inhalation (vapour) |
| Exposure time     | : 2 Years             |
| Result            | : negative            |

### Reproductive toxicity

May damage the unborn child.

### Components:

#### **N-Methyl-2-pyrrolidone:**

|                      |  |
|----------------------|--|
| Effects on fertility | : Test Type: Two-generation reproduction toxicity study<br>Species: Rat<br>Application Route: Ingestion<br>Method: OECD Test Guideline 416<br>Result: negative |
|----------------------|--|

|                               |   |
|-------------------------------|---|
| Effects on foetal development | : Test Type: Embryo-foetal development<br>Species: Rat<br>Application Route: Ingestion<br>Method: OECD Test Guideline 414<br>Result: positive |
|-------------------------------|---|

|  |  |
|--|--|
|  | : Test Type: Fertility/early embryonic development<br>Species: Rat<br>Application Route: inhalation (vapour)<br>Result: positive |
|--|--|

|  |   |
|--|---|
|  | : Test Type: Embryo-foetal development<br>Species: Rabbit<br>Application Route: Ingestion<br>Result: positive |
|--|---|

|                                    |  |
|------------------------------------|--|
| Reproductive toxicity - Assessment | : Clear evidence of adverse effects on development, based on animal experiments. |
|------------------------------------|--|

### **STOT - single exposure**

May cause respiratory irritation.

### Components:

#### **N-Methyl-2-pyrrolidone:**

|            |                                     |
|------------|-------------------------------------|
| Assessment | : May cause respiratory irritation. |
|------------|-------------------------------------|

### **STOT - repeated exposure**

Not classified based on available information.

**Buparvaquone Formulation**

Version 5.1      Revision Date: 2023/09/30      SDS Number: 2091179-00013      Date of last issue: 2023/04/04  
Date of first issue: 2017/10/17

---

**Repeated dose toxicity****Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male  
NOAEL : 169 mg/kg  
LOAEL : 433 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Method : OECD Test Guideline 408

Species : Rat  
NOAEL : 0.5 mg/l  
LOAEL : 1 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 96 Days  
Method : OECD Test Guideline 413

Species : Rabbit  
NOAEL : 826 mg/kg  
LOAEL : 1,653 mg/kg  
Application Route : Skin contact  
Exposure time : 20 Days

**Buparvaquone:**

Species : Cat  
NOAEL : 10 mg/kg  
Application Route : Intramuscular  
Exposure time : 5 d  
Remarks : No significant adverse effects were reported

NOAEL : 5 mg/kg  
Application Route : Intravenous  
Exposure time : 4 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 6 d  
Remarks : No significant adverse effects were reported

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

**Buparvaquone Formulation**

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

- |  |   |  |
|--|---|--|
| Toxicity to fish   | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l<br>Exposure time: 96 h  |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): > 1,000 mg/l<br>Exposure time: 24 h<br>Method: DIN 38412  |
| Toxicity to algae/aquatic plants                                       | : | ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l<br>Exposure time: 72 h<br><br>EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l<br>Exposure time: 72 h |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 12.5 mg/l<br>Exposure time: 21 d<br>Method: OECD Test Guideline 211   |
| Toxicity to microorganisms   | : | EC50: > 600 mg/l<br>Exposure time: 30 min<br>Method: ISO 8192  |

**Buparvaquone:**

- |   |   |  |
|---|---|--|
| Toxicity to fish                                    | : | LC50 (Brachydanio rerio (zebrafish)): 0.484 mg/l<br>Exposure time: 96 h<br>Method: OECD Test Guideline 203 |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.013 mg/l<br>Exposure time: 48 h<br>Method: OECD Test Guideline 202    |
| M-Factor (Acute aquatic toxicity)                   | : | 10   |
| M-Factor (Chronic aquatic toxicity)                 | : | 10   |

**Persistence and degradability****Components:****N-Methyl-2-pyrrolidone:**

- |                  |   |   |
|------------------|---|---|
| Biodegradability | : | Result: Readily biodegradable.<br>Biodegradation: 73 %<br>Exposure time: 28 d<br>Method: OECD Test Guideline 301C |
|------------------|---|---|

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

**Bioaccumulative potential****Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46  
Method: OECD Test Guideline 107

**Buparvaquone:**

Partition coefficient: n-octanol/water : log Pow: 6.5

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Buparvaquone)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(Buparvaquone)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082  
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)  
 Class : 9  
 Packing group : III  
 Labels : 9  
 EmS Code : F-A, S-F  
 Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

**Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

**Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances**

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

**Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials**

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

**The components of this product are reported in the following inventories:**

|       |   |                |
|-------|---|----------------|
| AICS  | : | not determined |
| DSL   | : | not determined |
| IECSC | : | not determined |

**16. OTHER INFORMATION**

Revision Date : 2023/09/30

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

## Buparvaquone Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 2023/04/04  |
| 5.1     | 2023/09/30     | 2091179-00013 | Date of first issue: 2017/10/17 |

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN